Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 18/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 18/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 18/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 11/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL10420651 | 0.98 | PDE4A (0.97) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL5400933 | 0.95 | PDE4A (0.91) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3842077 | 0.94 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381259 | 0.94 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL4623455 | 0.94 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9430034 | 0.93 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3990422 | 0.91 | ADORA2B (0.94) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9765669 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL7460178 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3186630 | 0.90 | PDE4A (0.94) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009118759-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD., (IN) | 2009-10-01 | — | — | WO | claimed |
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | YASUDA MASAHIRO | 2007-03-08 | — | — | US | claimed |
| JP-3677286-B2 | — | — | 2005-07-27 | — | — | JP | claimed |
| EP-1510222-A2 | Medicinal compositions promoting bowel movement | Eisai Co. Ltd. (JP) | 2005-03-02 | — | — | EP | claimed |
| US-20040259865-A1 | Pyrimidone compounds and pharmaceutical compositions containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-23 | — | — | US | claimed |
| US-20040106797-A1 | Novel xanthines having adenosine A1-receptor antagonist properties | ARYX THERAPEUTICS | 2004-06-03 | — | — | US | claimed |
| WO-2004009594-A2 | XANTHINE DERIVATIVES HAVING ADENOSINE A1-RECEPTOR ANTAGONIST PROPERTIES | ARYX THERAPEUTICS (US) | 2004-01-29 | — | — | WO | claimed |
| US-20030171383-A1 | Medicinal compositions promoting bowel movement | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-09-11 | — | — | US | claimed |
| EP-1283056-A1 | MEDICINAL COMPOSITIONS PROMOTING BOWEL MOVEMENT | Eisai Co., Ltd. (JP) | 2003-02-12 | — | — | EP | claimed |
| WO-1999031101-A1 | ADENOSINE RECEPTOR ANTAGONISTS WITH IMPROVED BIOACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 1999-06-24 | — | — | WO | claimed |
| EP-0167566-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | SUNSHINE ABRAHAM (US) | 1987-06-29 | — | — | EP | claimed |
| EP-0193599-A1 | XANTHINE DERIVATIVE PEST CONTROL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-09-10 | — | — | EP | claimed |
| EP-0165308-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1986-05-16 | — | — | EP | claimed |
| WO-1986001724-A1 | XANTHINE DERIVATIVE PEST CONTROL AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1986-03-27 | — | — | WO | claimed |
| US-4567183-A | SYNERGISTIC, POTENTIATION | ANALGESIC ASSOCIATES (US) | 1986-01-28 | — | — | US | claimed |
| EP-0167566-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE, Abraham (US) | 1986-01-15 | — | — | EP | claimed |
| EP-0165308-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1985-12-27 | — | — | EP | claimed |
| US-4558051-A | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same | RICHARDSON-VICKS, INC. (US) | 1985-12-10 | — | — | US | claimed |
| WO-1985002540-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | RICHARDSON-VICKS, INC. (US) | 1985-06-20 | — | — | WO | claimed |
| WO-1985002542-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1985-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | ADORA2B, ADORA2A, ADORA1 | PDE4A 55/4885PDE4B 47/4885PDE4C 143/4885 |
| US-20040106797-A1 | Novel xanthines having adenosine A1-receptor antagonist properties | ADORA1, ADORA2A, ADORA3 | PDE4A 23/4885PDE4B 55/4885PDE4C 87/4885 |
| US-20040259865-A1 | Pyrimidone compounds and pharmaceutical compositions containing the same | ADORA2A, ADORA1, ADORA3 | PDE4A 29/4885PDE4B 28/4885PDE4C 59/4885 |
| US-20030171383-A1 | Medicinal compositions promoting bowel movement | ADORA2A, ADORA3, ADORA2B | PDE4A 14/4885PDE4B 16/4885PDE4C 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.